Kiadis Pharma Announces Promising Phase II Clinical Trial Results f...(survival at 3 years post transplantation...),Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
Date:8/30/2007
survival at 3 years post transplantation. Based on these promising data, Kiadis Pharma will prepare for a clinical phase III study of Reviroc.
Dr. Denis-Claude Roy at Maisonneuve-Rosemont Hospital in Montreal, commented: "After more then five years of clinical research, we believe that our results demonstrate that Reviroc is able to improve patient survival. This is potentially a breakthrough achievement for patients suffering from Non-Hodgkin's lymphoma as well as their families."
About Reviroc
Reviroc is being developed as a treatment that eliminates blood cancer cells from autologous transplants for patients with end stage blood cancer. An autologous transplant uses the patient's own bone marrow to serve as a graft. Bone marrow transplantations are broadly recognized as a treatment option for patients suffering from blood cancers, such as leukemia and lymphoma. Reviroc has been developed to remove residual tumor cells from the graft.
About Kiadis Pharma
Kiadis Pharma is an oncology focused pharmaceutical development company with four products in different phases of clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address high unmet medical needs. Key areas for Kiadis Pharma are clinical indications in blood cancers and solid tumors. Kiadis Pharma is headquartered in the Netherlands with facilities in Groningen, the Netherlands and Montreal, Canada. For more information about Kiadis Pharma, please visit http://www.kiadis.com
'/>"/>
| SOURCE Kiadis Pharma Copyright©2007 PR Newswire. All rights reserved |
Related medicine technology :
1. Sygnis Pharma AG announces date for presentation of clinical results
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
Breaking Medicine Technology:Van Andel Institute Cuts Ribbon on $178 Million Expansion 2Van Andel Institute Cuts Ribbon on $178 Million Expansion 3Van Andel Institute Cuts Ribbon on $178 Million Expansion 4Merieux Alliance Becomes Institut Merieux 2Merieux Alliance Becomes Institut Merieux 3Merieux Alliance Becomes Institut Merieux 4New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3UAB researchers looking for genetic predictors for suicide 9855 1UAB researchers looking for genetic predictors for suicide 9855 2Blue Shield of California to Cover H1N1 Flu Vaccine Administration for All Members 56676 1Blue Shield of California to Cover H1N1 Flu Vaccine Administration for All Members 56676 2MRSA May Succumb to Honey 56675 1MRSA May Succumb to Honey 56675 2
Other Medicine Technology:Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro) 2Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro) 3New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models 2New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models 3New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models 4New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models 5
Breaking Medicine News(10 mins):Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 3Health News:Lilly Announces the First 300-unit Vial of Insulin 2Health News:Lilly Announces the First 300-unit Vial of Insulin 3Health News:Lilly Announces the First 300-unit Vial of Insulin 4Health News:Don't I know you? University of Toronto research sheds light on memorial retrieval 2Health News:Docs Not Giving Clear Advice on Infant Sleep Positions 2Health News:Docs Not Giving Clear Advice on Infant Sleep Positions 3
[0] Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards [0] Lilly Announces the First 300-unit Vial of Insulin[0] Nearly 3 Million Doses of H1N1 Vaccine Allocated to Pennsylvania since Start of Vaccination Effort[1] Don't I know you? University of Toronto research sheds light on memorial retrieval[1] Docs Not Giving Clear Advice on Infant Sleep Positions
Other Medicine News:Health News:Drive or Die 2Health News:Drive or Die 3Health News:Researchers discover ways of integrating treatment of traumatized Tibetan refugee monks 2Health News:Researchers discover ways of integrating treatment of traumatized Tibetan refugee monks 3Health News:Haemacure Reports First Quarter 2009 Results and Hires Advisor for the Sale or Merger of the Company 2Health News:Haemacure Reports First Quarter 2009 Results and Hires Advisor for the Sale or Merger of the Company 3Health News:VIDEO From Medialink and the American Heart Association: 'Better Fats' Benefit Heart Health 2Health News:Injected Medication Errors a Major Problem 2Health News:MESSA Receives National Recognition for Best Practices in Providing Efficient, Cost-Effective Customer Service 2Health News:MESSA Receives National Recognition for Best Practices in Providing Efficient, Cost-Effective Customer Service 3
Drive or DieResearchers discover ways of integrating treatment of traumatized Tibetan refugee monksHaemacure Reports First Quarter 2009 Results and Hires Advisor for the Sale or Merger of the CompanyVIDEO From Medialink and the American Heart Association: 'Better Fats' Benefit Heart HealthInjected Medication Errors a Major ProblemMESSA Receives National Recognition for Best Practices in Providing Efficient, Cost-Effective Customer Service
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |